Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10123610 | 0.76 | TRPV4 (0.33) | TRPV4KDM4EMEN1KMT2A | |
| SCHEMBL10123607 | 0.72 | KDM4E (0.33) | KDM4EMEN1KMT2A | |
| SCHEMBL10123586 | 0.69 | TSHR (0.35) | KDM4EMEN1KMT2AAR | |
| SCHEMBL10123590 | 0.67 | ALDH1A1 (0.33) | TRPV4CYP11B1CYP11B2KDM4EKMT2A | |
| SCHEMBL10123589 | 0.67 | TSHR (0.36) | KDM4E | |
| SCHEMBL10123648 | 0.65 | AR (0.37) | AR | |
| SCHEMBL57346 | 0.65 | TRPV4 (0.61) | TRPV4CYP11B1CYP11B2AR | |
| SCHEMBL30919072 | 0.65 | TRPV4 (0.61) | TRPV4CYP11B1CYP11B2AR | |
| SCHEMBL20944522 | 0.64 | L3MBTL1 (0.38) | — | |
| SCHEMBL10123643 | 0.62 | TSHR (0.39) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748452-B2 | Indolizine derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-06-10 | — | — | US | disclosed |
| US-8748452-B2 | Indolizine derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-06-10 | — | — | US | disclosed |
| US-20120015972-A1 | INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120015972-A1 | INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015972-A1 | INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, INMT, PON1 | TRPV4 4205/4885CYP11B1 53/4885CYP11B2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.